

Lawrence Berkeley National Laboratory

LBL Publications

Title

Clinical Variants of New Delhi Metallo- β -Lactamase Are Evolving To Overcome Zinc Scarcity

Permalink

<https://escholarship.org/uc/item/73x137tq>

Journal

ACS Infectious Diseases, 3(12)

ISSN

2373-8227

Authors

Stewart, Alesha C
Bethel, Christopher R
VanPelt, Jamie
[et al.](#)

Publication Date

2017-12-08

DOI

10.1021/acsinfecdis.7b00128

Peer reviewed

Clinical Variants of New Delhi Metallo- β -Lactamase Are Evolving To Overcome Zinc Scarcity

Alesha C. Stewart,[†] Christopher R. Bethel,[§] Jamie VanPelt,[‡] Alex Bergstrom,[‡] Zishuo Cheng,[‡] Callie G. Miller,[‡] Cameron Williams,[‡] Robert Poth,[‡] Matthew Morris,[‡] Olivia Lahey,[‡] Jay C. Nix,^{||} David L. Tierney,^{*,‡} Richard C. Page,^{*,‡} Michael W. Crowder,^{*,‡} Robert A. Bonomo,^{*,§,⊥} and Walter Fast^{*,†}

[†]Division of Chemical Biology and Medicinal Chemistry, College of Pharmacy, and the LaMontagne Center for Infectious Disease, University of Texas, Austin, Texas 78712, United States


[‡]Department of Chemistry and Biochemistry, Miami University, Oxford, Ohio 45056, United States

[§]Research Services, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio 44106, United States

^{||}Molecular Biology Consortium, Beamline 4.2.2, Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States

[⊥]Departments of Medicine, Pharmacology, Molecular Biology and Microbiology, Biochemistry, Proteomics and Bioinformatics, and the CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology, Cleveland, Ohio 44106, United States

Supporting Information



ABSTRACT: Use and misuse of antibiotics have driven the evolution of serine β -lactamases to better recognize new generations of β -lactam drugs, but the selective pressures driving evolution of metallo- β -lactamases are less clear. Here, we present evidence that New Delhi metallo- β -lactamase (NDM) is evolving to overcome the selective pressure of zinc(II) scarcity. Studies of NDM-1, NDM-4 (M154L), and NDM-12 (M154L, G222D) demonstrate that the point mutant M154L, contained in 50% of clinical NDM variants, selectively enhances resistance to the penam ampicillin at low zinc(II) concentrations relevant to infection sites. Each of the clinical variants is shown to be progressively more thermostable and to bind zinc(II) more tightly than NDM-1, but a selective enhancement of penam turnover at low zinc(II) concentrations indicates that most of the improvement derives from catalysis rather than stability. X-ray crystallography of NDM-4 and NDM-12, as well as bioinorganic spectroscopy of dizinc(II), zinc(II)/cobalt(II), and dicobalt(II) metalloforms probe the mechanism of enhanced resistance and reveal perturbations of the dinuclear metal cluster that underlie improved catalysis. These studies support the proposal that zinc(II) scarcity, rather than changes in antibiotic structure, is driving the evolution of new NDM variants in clinical settings.

KEYWORDS: antibiotic resistance, β -lactamase, zinc, nutritional immunity, evolution

Since the first report of New Delhi metallo- β -lactamase (NDM), now a worldwide, community-acquired, antibiotic-resistance determinant in Enterobacteriaceae, 18 different variants of this metallo- β -lactamase (MBL) containing altered amino acid sequences have been identified from the clinic or from infected animals.^{1–19} The emergence of these NDM variants raises a number of questions: How do the variations impact function? What selective pressure drives the changes?

Will the variants impact clinical outcomes? Some of these questions have been previously addressed for serine β -lactamases. For instance, extended-spectrum- β -lactamases are an infamous example for which the use and misuse of β -lactam drugs appear to have driven the evolution of variants with

Received: August 21, 2017

Published: September 30, 2017

altered substrate selectivity that can accommodate new substrate classes and thus extend antibiotic resistance.^{20,21} However, NDM is already a highly efficient catalyst with broad substrate selectivity that encompasses all of the clinically used classes of β -lactams, except monobactams.^{18,22} A need to alter substrate selectivity may not be a significant selective pressure placed on NDM-encoding microorganisms. In support of this idea, it is notable that most of the identified NDM variants confer only limited changes in catalytic activity and substrate selectivity. In contrast, a number of NDM variants have significantly increased thermal stability, which could impact antibiotic resistance by extending the lifetime of the enzyme.²² Clearly, there are different mechanisms by which NDM variants could enhance antibiotic resistance. Herein, we investigate an alternative hypothesis, that some naturally occurring NDM variants enhance the ability of the enzyme to function at low zinc(II) ion concentrations relevant at typical sites of infection.

Competition between host and pathogen for scarce and essential metal ions at an infection site is well established for iron.²³ The Fe(III) ion has limited aqueous solubility (1.4 nM), and pathogens have evolved structurally diverse siderophores to effectively compete with host proteins for binding iron ions.^{24,25} The proposal that host and pathogen may also compete for zinc(II) is also supported.²³ Humans secrete the proteins calprotectin and psoriasin, which can sequester zinc(II) and inhibit microbial infections.²⁶ The total zinc(II) concentration in *Escherichia coli* is ca. 200 μ M, but almost all of these ions are protein-bound, with most binding to the ribosome.^{27,28} Metalloregulatory proteins in *E. coli* are triggered at femtomolar concentrations of zinc(II).²⁷ Some bacteria have zinc(II)-selective transporters (e.g., the ZnuABC transporter in *E. coli*), and the siderophores pyridine-pyridine-2,6-dithiocarboxylic acid and yersiniabactin can also transport zinc(II), essentially acting as zincophores.²⁹ Taken together, these observations suggest that competition for zinc(II) ions might provide a selective pressure driving the evolution of pathogens.

NDM requires metal ions for activity and has been characterized as a dizinc hydrolase. Zinc(II) ions are bound in adjacent Zn1 and Zn2 sites, forming a dinuclear zinc(II) ion cluster.³⁰ In a proposed catalytic mechanism, the metal ions work in tandem to depress the pK_a of a bridging hydroxide nucleophile; Zn1 polarizes the β -lactam carbonyl oxygen and stabilizes a tetrahedral adduct, and Zn2 stabilizes the developing negative charge on the leaving group nitrogen (Figure 1A).³¹ This metalloenzyme may have some advantages when competing for metal ion binding because its periplasmic location could facilitate access to extracellular zinc and because some metallo- β -lactamases can substitute alternative divalent metal ions if zinc(II) is not available.^{31–34} The Zn1 of NDM-1 is bound tightly, and the Zn2 site has a K_d value estimated, by changes in activity, to be in the low micromolar range (2 μ M).³⁵ The concentration of zinc(II) at typical infection sites appears to be in a similar range. Blood plasma has approximately 6 μ M labile zinc(II) and 12 μ M bound zinc(II) ions.³⁶ Lung sputum from healthy and cystic fibrosis patients contains 0.2–28 μ M zinc(II), and urine contains 0.6–10 μ M zinc(II) ions.^{36–39} Laboratory selection experiments suggest that zinc(II) scarcity may be a selective pressure driving evolution of MBL genes. Artificial variants of a MBL with decreased zinc(II) affinity are less able to confer resistance to cells cultured using low zinc(II) concentrations.⁴⁰ Specifically, the unusual N-terminal lipidation of NDM has been shown to confer stability that allows NDM to resist degradation at low




Figure 1. Structures of selected β -lactams and hydrolysis by NDM-1. (A) Abbreviated catalytic mechanism for NDM-1 catalyzed hydrolysis of β -lactams. For a more complete, proposed mechanism, see ref 31. (B) Structures of selected β -lactam structures with the (core scaffold) shown in bold: ampicillin (penam), meropenem (carbapenem), and chromacef (cephem).

zinc(II) concentrations.⁴¹ Herein, we demonstrate that the M154L substitution found in almost half of all clinical NDM variants decreases antibiotic sensitivity to specific β -lactams at low zinc(II) concentrations. This effect is facilitated, at least in part, by enhanced affinity of these NDM variants for Zn2, suggesting that NDM-bearing bacteria are evolving to overcome the selective pressure of zinc(II) scarcity on antibiotic resistance.

RESULTS AND DISCUSSION

Of the 18 variants of NDM identified from clinical samples or animals, 50% contain a substitution at Met154 (NDM-4: M154L; NDM-5: V88L, M154L; NDM-7: D130N, M154L; NDM-8: D130G, M154L; NDM-11: M154V; NDM-12: M154L, G222D; NDM-13: D95N, M154L; NDM-15: M154L, A233V; NDM-17: V88L, M154L, E170K), with all except NDM-11 incorporating a Leu residue. This change is the most common substitution found in all naturally occurring NDM variants. Although the variants were identified in geographically distant sources, each of the Leu substitutions are encoded by a CTG codon that presumably arose from A to C point mutation(s) of the Met codon (ATG) found in NDM-1. Since the Leu for Met substitution is quite conservative, the potential for significant structural or functional changes did not, at first, appear high. Inspection of the surrounding protein environment in a crystal structure of NDM-1 revealed that the M154 side chain neighbors the α -carbon of His122, a residue that serves as a Zn1 ligand and is part of a short helical segment that also contains the Zn2 ligand Asp124.³⁰ As previously established in other metalloproteins, changes in second-shell and surrounding residues have the potential to significantly affect active-site metal ion affinity and preference.⁴² Therefore,

due to the prevalence of the M154L substitution in naturally occurring NDM variants and the proximity of this substitution to the dinuclear zinc cluster, we focused on characterizing differences between NDM-1 and NDM-4 (M154L). NDM-12 (M154L, G222D) was also included in the comparison to see if any differences imparted by M154L might be retained or altered in the presence of additional substitutions.

Using methods previously established with NDM-1, we overexpressed and purified NDM-1, NDM-4, and NDM-12.^{35,43} To assay substrate selectivity, we chose substrates to represent three different classes of β -lactam drugs (Figure 1B): ampicillin (penams), meropenem (carbapenems), and cephalothin (cephems). Chromacef (a cephem) was also included as a common β -lactam substrate in laboratory assays.⁴⁴ For each substrate, we determined steady-state kinetic parameters with NDM-1, -4, and -12, with all assays supplemented by 10 μ M ZnSO₄ to provide the optimum zinc(II) concentration previously determined for NDM-1 with all three types of substrate (Table 1).³⁵ Although there are differences observed

Table 1. Steady-State Kinetic Parameters for NDM Variants Supplemented with Optimum ZnSO₄ (10 μ M)

substrate and variant	k_{cat} (s ⁻¹)	K_M (μ M)	k_{cat}/K_M (M ⁻¹ s ⁻¹)
ampicillin			
NDM-1	810 \pm 40	240 \pm 40	3.4 \times 10 ⁶
NDM-4	1440 \pm 90	580 \pm 70	2.5 \times 10 ⁶
NDM-12	450 \pm 20	260 \pm 40	1.7 \times 10 ⁶
meropenem			
NDM-1	160 \pm 10	240 \pm 30	0.7 \times 10 ⁶
NDM-4	150 \pm 30	360 \pm 90	0.4 \times 10 ⁶
NDM-12	85 \pm 5	130 \pm 20	0.6 \times 10 ⁶
cephalothin			
NDM-1	123 \pm 3	17 \pm 2	7.2 \times 10 ⁶
NDM-4	86 \pm 2	14 \pm 1	6.1 \times 10 ⁶
NDM-12	54 \pm 1	10 \pm 1	5.4 \times 10 ⁶
chromacef			
NDM-1	7.7 \pm 0.3	1.6 \pm 0.2	4.8 \times 10 ⁶
NDM-4	4.9 \pm 0.1	0.7 \pm 0.1	7.0 \times 10 ⁶
NDM-12	3.9 \pm 0.2	3.5 \pm 0.6	1.1 \times 10 ⁶

for each parameter (k_{cat} , K_M , and k_{cat}/K_M) when NDM-1, -4, and -12 are compared, the differences are only of minor magnitude (<5-fold), a finding that corroborates other published comparisons of substrate hydrolysis kinetics among naturally occurring NDM variants.²²

Previously, we found that the zinc dependence of NDM-1 activity differs with the structural class of β -lactam used in the assay.³⁵ Under conditions of saturating (or near-saturating) substrate, the rate of NDM-1-catalyzed hydrolysis of penam substrates decreased significantly at low zinc concentrations. Carbapenem substrates showed a similar trend, but the loss of activity was of lesser magnitude. Cephalosporin substrates did not show loss of activity at low zinc concentrations. The effect of substrate structure on zinc dependence could stem from the possibility of bound substrate enhancing Zn₂ affinity or from the possibility that Zn₂ is more essential for catalyzing the hydrolysis of some substrates than others.^{45–47} For example, the cephem we tested (e.g., chromacef) have a β -lactam nitrogen leaving group in conjugation with strongly electron withdrawing groups that can facilitate lactam hydrolysis. This type of substrate would be the least reliant on Zn₂ to stabilize the leaving group (Figure 1) and show the least dependence on

zinc(II) concentrations. The carbapenems we tested have substituents that are less electron withdrawing and show a more moderate dependence on zinc(II) concentrations. The penams do not have an electron withdrawing group in conjugation with the leaving group and would be most dependent on Zn₂ for leaving group stabilization. Accordingly, hydrolysis of these penam substrates exhibit the most dramatic dependence on zinc(II) concentration. Regardless of the exact mechanism, we hypothesized that naturally occurring NDM variants might have evolved to bind zinc(II) more tightly and to confer stability or enhanced catalysis under conditions of zinc(II) scarcity and therefore tested the zinc(II) dependence of these variants for turnover of various substrates.

The relative activities of NDM-1, -4, and -12 with saturating substrate concentrations (when possible) were plotted and normalized to the maximum initial rate of each variant to depict the zinc(II) dependence (Figure 2). For cephalothin (a




Figure 2. Zinc(II) dependence of NDM variants for hydrolysis of various β -lactams. When possible, measurements were taken with saturating concentrations of substrates using stocks of “as-purified” monozinc NDM variants, with increasing ZnSO₄ concentrations in the assay solution, as described in the Methods. The variants NDM-1 (black \bullet), NDM-4 (M154L, blue \blacktriangle), and NDM-12 (M154L, G222D, red \blacksquare) were assayed with the cephalosporin cephalothin (A, 300 μ M), the carbapenem meropenem (B, 300 μ M), and the penam ampicillin (C, 1 mM). Error bars represent the largest deviation of the mean from two experiments.

cephem), we observed only minimal changes in activity with decreasing zinc(II) concentration, similar to the behavior of nitrocefin with NDM-1.³⁵ For meropenem (a carbapenem), we observe a moderate decrease of activity at low zinc(II) concentrations for NDM-1, but the magnitude of the decrease is less for NDM-4 and NDM-12. Most dramatically, we observed a significant loss in NDM-1 activity with ampicillin (a

penam) at low zinc(II) concentrations, but activity is instead retained by NDM-4 and NDM-12. The loss of ampicillin turnover by NDM-1 under these conditions reflects changes in k_{cat} , since the K_M values for each variant decrease under low zinc(II) concentrations (Table 2). In sum, at low zinc(II)

Table 2. Steady-State Kinetic Parameters for NDM Variants Supplemented with Minimal ZnSO₄ (1 nM)

substrate and variant	k_{cat} (s ⁻¹)	K_M (μM)	k_{cat}/K_M (M ⁻¹ s ⁻¹)
ampicillin			
NDM-1	300 ± 10	60 ± 8	5 × 10 ⁶
NDM-4	1050 ± 50	290 ± 40	3.6 × 10 ⁶
NDM-12	400 ± 20	200 ± 20	2.0 × 10 ⁶

concentrations, the retention of NDM activity for each variant is dependent on the type of substrate used. Specifically with the penam ampicillin, the clinical variants NDM-4 and NDM-12 maintain their activity significantly better than NDM-1 when zinc(II) ions are scarce.

We next sought to determine if these NDM variants also showed different zinc(II) dependent behavior when challenged in cell culture and if this effect differed depending on the class of β-lactam antibiotic used. We determined minimum inhibitory concentrations (MIC) of antibiotics from the three structural classes of β-lactams examined above using “standard” conditions and using conditions designed to mimic zinc(II) scarcity by including the metal chelator ethylenediaminetetraacetic acid (EDTA). Use of EDTA to limit zinc(II) ion availability for microbial growth has been described previously.⁴⁰ In general, the MIC values determined using limited zinc(II) concentrations were much lower than those determined using standard conditions for all strains and antibiotics, reflecting an impaired ability of all NDM variants to confer resistance at zinc(II) concentrations similar to those at typical sites of infection (Table 3). Strains of *E. coli* harboring

Table 3. MIC Values for NDM Variants and Various β-Lactams in “Standard” and Zinc(II) Limited Conditions

strain	antibiotic	MIC (mg/L) standard conditions ^b	MIC (mg/L) EDTA (50 μM) ^b
pHSG298 ^a	ampicillin	2	2
NDM-1	ampicillin	>8192	128
NDM-4	ampicillin	>8192	8192
NDM-12	ampicillin	>8192	>8192
pHSG298	meropenem	≤0.06	≤0.06
NDM-1	meropenem	32	0.125
NDM-4	meropenem	32	0.5
NDM-12	meropenem	32	2
pHSG298	cephalothin	4	4
NDM-1	cephalothin	>1024	128
NDM-4	cephalothin	>1024	512
NDM-12	cephalothin	>1024	512

^aVector-only control. ^bResults are from three biological replicates.

the same plasmid, but lacking the *bla*_{NDM} gene, have the same MIC values in both conditions, showing the effect is NDM dependent. A more detailed analysis reveals that the magnitude of the zinc(II) dependence of the NDM variants is different depending on which antibiotic is used (Table 3; structures are shown in Figure S1). Under standard conditions, differences in MIC values for ampicillin were not observed among the

variants, but at concentrations where zinc(II) is scarce, the MIC values for NDM-4 and NDM-12 were dramatically higher (≥64-fold), indicating that much higher antibiotic concentrations were required to inhibit cell growth. The standard conditions used with carbapenems meropenem and imipenem did not show differences in MIC values between variants, but conditions that mimic zinc(II) scarcity revealed a moderate increase in MIC values for NDM-4 and NDM-12 over NDM-1 (4-fold and 16-fold increase for meropenem (Table 3) and 4-fold and 8-fold increase for imipenem (Table S1), respectively), indicating that these variants can better enhance cell viability at low zinc(II) concentrations. Finally, the cepheims cephalothin, ceftazidime, cefotaxime, and cefepime all did not show differences in MIC values between NDM variants under standard conditions (cephalothin MIC values are shown in Table 3 and the other cepheims in Tables S2–S5). Conditions mimicking zinc(II) scarcity reveal some increases in MIC values that ranged in magnitude from >1- to 16-fold, depending on the structure of the antibiotic. In sum, the zinc(II) scarcity limits the ability of NDM to provide antibiotic resistance. Notably, the increase in cell viability conferred by NDM-4 and NDM-12 was not uniform for all classes of β-lactams but instead showed a significantly larger effect on ampicillin, consistent with the substrate-specific changes observed *in vitro* using enzyme kinetics.

To obtain a better mechanistic understanding of these effects, we constructed a panel of *E. coli* strains containing plasmids encoding 20 different amino acids at the 154 position of NDM. The MIC values for these strains under standard and scarce zinc(II) conditions were determined for the same panel of antibiotics described above. The results with ampicillin (Table 4) are representative of most of the other antibiotics tested (Tables S1–S6). Under standard conditions, the M154L variant has the same MIC value as NDM-1. Other substitutions

Table 4. MIC Values for Ampicillin with NDM Variants Substituted at Position 154 in Standard and Zinc(II) Limited Conditions

strain	MIC (mg/L) standard conditions ^b	MIC (mg/L) EDTA (50 μM) ^b
NDM 154M ^a	>8192	128
NDM 154L ^a	>8192	8192
NDM 154I	>8192	128
NDM 154F	8192	64
NDM 154V	>8192	128
NDM 154W	8192	16
NDM 154G	2048	8
NDM 154Q	>8192	32
NDM 154K	2048	8
NDM 154E	1024	4
NDM 154A	4096	8
NDM 154D	64	4
NDM 154N	8192	8
NDM 154P	64	4
NDM 154S	4096	8
NDM 154T	8192	8
NDM 154Y	8192	16
NDM 154C	4096	8
NDM 154H	>8192	16
NDM 154R	4096	8

^aValues are taken from Table 3. ^bResults from three biological replicates.




Figure 3. Expression levels of NDM in *E. coli* DH10B cells carrying pHSG-298/*bla*_{NDM-1} and M154 variants grown in MH broth to log phase. DNaK was used as a loading control (top band). Purified NDM-1 (200 ng) was used as a control.

at this position generally result in either equivalent MIC values or MIC values that are substantially decreased. The latter effect indicates increased sensitivity to β -lactams, likely due to lowered NDM concentration (Figure 3), structure, function, or a possible combination of effects. The substitutions at position 154 most deleterious for MIC values of each of the antibiotics tested are consistently the nonconservative substitutions Asp or Pro. Low MIC values due to the Pro substitution can likely be attributed to lower expression or stability, but the lowered MIC values of the Asp variant are instead more likely to stem from changes in activity (Figure 3). We note an interesting Trp substitution that retains MIC values even with significantly lowered expression. Next, the panel of mutants was tested in low zinc(II) concentrations, which reveal the unique advantage conferred by the Leu substitution. All other substitutions at this position result in MIC values equal to, or considerably less than, Met (NDM-1). With all the antibiotics tested, the substitutions that are most similar to Leu, M154I and M154V, typically had the second highest MIC values, ranking either equal to Met or resulting in MIC values one or two dilutions below. Accordingly, the only other naturally occurring variant found to encode a non-Leu substitution at this position contains a Val (NDM-11). In sum, Leu is the only substitution at position 154 that improves cell viability when treated with β -lactams under conditions of zinc(II) scarcity.

Because the selective advantages of the NDM-4 and NDM-12 variants are only revealed at low zinc(II) concentrations, we sought to determine whether these variants have altered affinity for Zn²⁺ (the labile zinc in NDM-1³⁵). An established colorimetric assay⁴⁸ was used to monitor competition for binding zinc(II) between a small molecule complex with the colored zinc chelator, 4-(2-pyridylazo)resorcinol (PAR), when challenged by addition of monozinc NDM variants. Removal of zinc(II) from the PAR complex and subsequent binding to an NDM variant was expected to result in a decrease in absorbance, and these changes can be fitted to determine the K_d of the open metal-binding site in each NDM variant (Figure 4). The K_d determined for NDM-1 ($18.6 \pm 0.7 \mu\text{M}$) is in the low micromolar range, and this protein has the weakest affinity. Notably, affinity for zinc(II) is improved in both of the other variants: NDM-4 ($K_d = 10.0 \pm 0.8 \mu\text{M}$); NDM-12 ($K_d = 6.6 \pm 0.9 \mu\text{M}$). These values are slightly higher than the Zn²⁺ K_d determined earlier for NDM-1 using activity assays, but the difference may be attributable to the presence of substrate, which has been shown to alter zinc(II) K_d values in other MBLs.^{46,47} Since zinc(II) binding might also stabilize enzyme




Figure 4. Competition for zinc(II) between NDM variants and PAR. Solutions of PAR ($10 \mu\text{M}$) and ZnSO_4 ($4 \mu\text{M}$) were titrated with monozinc NDM-1 (black ●), NDM-4 (M154L, blue ▲), or NDM-12 (M154L, G222D, red ■). Fitting methods to derive the respective K_d values (18.6 ± 0.7 , 10.0 ± 0.8 , and $6.6 \pm 0.9 \mu\text{M}$) are referenced in the Methods.

structure, we assayed the zinc(II) dependence on protein stability of NDM-1, -4, and -12. Here, we used differential scanning fluorimetry as a metric of protein stability and determined melting temperatures (T_m 's) for each NDM variant at different zinc(II) concentrations (Figure 5). NDM-1 showed




Figure 5. Differential scanning fluorimetry of NDM variants with varying zinc(II) concentrations. Melting points for NDM-1 (black ●), NDM-4 (M154L, blue ▲), and NDM-12 (M154L, G222D, red ■) were determined by differential scanning fluorimetry at a range of ZnCl_2 concentrations from 0.25 to $80 \mu\text{M}$. Fitting methods to derive the respective midpoints of the transitions (NDM-1 = $5.06 \pm 0.09 \mu\text{M}$; NDM-4 = $4.69 \pm 0.04 \mu\text{M}$; NDM-12 = $3.70 \pm 0.1 \mu\text{M}$) are described in the Methods.

the lowest T_M (57.2 ± 0.3 °C) at high zinc(II) concentrations that fill both Zn1 and Zn2 sites. The T_M 's for NDM-4 (59.5 ± 0.1 °C) and NDM-12 (61.7 ± 0.2 °C) are successively larger under the same conditions. At lowered zinc(II) concentrations, the T_M values are, on average, approximately 20 °C lower than those of the fully metalated protein, signifying a significant role for stabilization of the global NDM fold through binding zinc(II). The T_M values of NDM-1, NDM-4, and NDM-12 are all similar at low zinc(II) concentrations, but the T_M of NDM-4 (40.6 ± 0.1 °C) is slightly higher than NDM-1 and NDM-12 (NDM-12 = 36.8 ± 0.6 °C, NDM-1 = 39.1 ± 0.3 °C) with P values of 0.012 and 0.031, respectively, as determined by Student's t -test. When compared with an earlier report²² containing T_M 's for NDM-1 and NDM-4, the values at high zinc(II) concentrations are quite similar, but T_M 's at low zinc(II) concentrations differ significantly (approximately 20 °C), likely reflecting differences in the initial metal ion content of the proteins used in each study (the earlier report does not list initial metal ion content of the proteins; the experiments here start with the apo protein). In our current work, we note that the transition between the T_M 's at high and low zinc(II) concentrations occur at similar values to those determined for Zn2 K_d and also show the same rank order for the variants (NDM-1 (5.06 ± 0.09 μ M) > NDM-4 (4.69 ± 0.04 μ M) > NDM-12 (3.7 ± 0.1 μ M)). Since the DSF system is not at equilibrium and, like the kinetic method, involves additional ligands which might impact zinc(II) affinity, the transitions are not fit as K_d values. However, they do illustrate the importance of metal binding to protein stability and reveal enhanced stability for the metal-bound variants NDM-4 and NDM-12.

The increase in stability of the metal-bound forms of NDM-4 and NDM-12 over NDM-1 could contribute to increased MIC values of these variants in conditions of zinc(II) scarcity. MIC values for NDM-4 and NDM-12 increased for almost all β -lactams that we tested at low zinc(II) concentrations. However, a global effect on protein stability would predict a similar magnitude of increase for all classes of β -lactams. In contrast, the low zinc(II) concentrations used in both the enzyme activity assays and MIC studies reveal a particularly large improvement for NDM-4 and NDM-12 that is specific for the substrate ampicillin, suggesting instead that improvements in catalysis, rather than overall protein stability, play a more dominant role in enhancing cell survival with this penam when zinc(II) is scarce.

To determine the impact of changes in NDM-4 and NDM-12 on protein structure, we determined the X-ray crystal structures of each. Data collection, refinement, and geometric quality statistics are provided in Table 5. Our structure of NDM-4 was solved in space group $P12_1$ and contains two chains within the asymmetric unit. While this is the same space group as an existing NDM-4 structure in the PDB (accession ID 4TYF),⁴⁹ the existing structure (4TYF) contains only one chain per asymmetric unit. Despite this difference in unit cell parameters and asymmetric unit composition, the two chains within our structure of NDM-4 superimpose with 0.16 and 0.19 Å RMSD to the existing NDM-4 structure. This is the first report of a NDM-12 structure. Our structure of NDM-12 was solved in space group $P12_1$, contains a single chain per asymmetric unit, and features unit cell dimensions similar to the existing NDM-4 structure (4TYF). Superimposition of the structural models of NDM-1, NDM-4, and NDM-12 reveals only small changes in the overall structure. Each chain within our structure of NDM-4 superimposes with 0.22 and 0.23 Å

Table 5. X-ray Crystallography Data Collection and Refinement Statistics for NDM-4 and NDM-12

	NDM-4 _{42–270}	NDM-12 _{42–270}
Data Collection		
beamline	ALS 4.2.2	ALS 4.2.2
wavelength (Å)	1.0000	1.0000
space group	$P12_1$	$P12_1$
a, b, c (Å)	41.4, 59.2, 84.5	41.6, 58.7, 41.7
α, β, γ (deg)	90, 98.7, 90	90, 98.6, 90
resolution range ^a (Å)	39.18–1.40 (1.45–1.40)	33.72–1.35 (1.40–1.35)
reflections ^a	280 017 (27 179)	135 100 (6384)
unique reflections ^a	79 231 (7915)	41 682 (3103)
completeness ^a (%)	99.6 (99.9)	95.7 (72.0)
Wilson B -factor	13.3	13.2
redundancy	3.5 (3.4)	3.2 (2.1)
mean $I/\sigma I$	9.68 (0.81)	14.71 (0.90)
$CC_{1/2}$ ^a	0.998 (0.396)	0.999 (0.442)
Refinement		
number of reflections	79 193 (7907)	41 678 (3102)
PDB ID	SWIG	SWIH
R_{work}/R_{free}	0.200/0.225	0.188/0.222
number of atoms (protein/water/ ligands)	3,452/608/4	1,926/233/2
average B -factors (protein/water/ ligands)	19.44/30.71/18.26	20.94/34.97/22.73
Model Quality		
bond lengths rmsd (Å)	0.011	0.009
bond angles rmsd (deg)	1.46	1.10
Ramachandran favored (%)	98.24	98.24
Ramachandran outliers (%)	0.00	0.00
poor rotamers ^b (%)	0.86	1.19
$C\beta$ deviations >0.25 Å ^b	0	0
clash score ^b	3.09	2.42
clash percentile ^b	97th percentile ($N = 480$; 1.40 Å \pm 0.25 Å)	99th percentile ($N = 466$; 1.35 Å \pm 0.25 Å)
MolProbity score ^b	1.10	1.08
MolProbity score percentile ^b	99th percentile ($N = 3363$; 1.40 Å \pm 0.25 Å)	99th percentile ($N = 3057$; 1.35 Å \pm 0.25 Å)

^aValues in parentheses represent data for the highest resolution shell.

^bCalculated with MolProbity v4.3.1.⁶⁴

RMSD to an existing structure of NDM-1 (accession ID 4EXY), and our NDM-12 structure superimposes with 0.26 Å RMSD to NDM-1 (4EXY).

The N- and C-terminal sequences of the proteins have minor differences in conformation; Asn220 is placed as a different rotamer in NDM-4, and the putative substrate-binding β -hairpin loop (residues 63–74) is angled differently among the variants (not shown). These differences likely represent the normal range of conformations available to NDM in solution. A view focused around M154L, G222D, and the active-site zinc(II) cluster (Figure 6A) shows the proximity of the Met154 side chain to the α -carbon of the Zn1 ligand His122, as well as to the short helical region that contains the Zn2 ligand Asp124. These structures show that the M154L and G222D mutations do not impart any large structural perturbations in the active-site zinc(II) cluster or primary and secondary shell ligands in NDM. The mechanism whereby G222D imparts a functional change is not readily apparent from the structure, although this loop borders the active site, and changes in flexibility upon substitution of Gly would not necessarily be visualized in the




Figure 6. Superimposition of structures for NDM variants. The structural models for NDM-1 (gray; protein data bank accession code 4EXY⁶⁶), NDM-4 (M154L, teal), and NDM-12 (M154L, G222D, pink) are superimposed using PyMOL with some atoms omitted for clarity. The large spheres in panels A–C represent the Zn1 (1) and Zn2 (2) sites, and the smaller spheres represent ordered water molecules (or bridging hydroxide ion). Atom labels and spheres are colored with respect to the NDM variant to which they belong or in black if the label refers to all three structures. (A) A stereo image indicates the position of residues that coordinate Zn1 and Zn2, as well as the positions of the M154L and G222D mutations. (B) A close-up view of NDM-4 and NDM-12 L154 (side chains shown as spheres) demonstrates how the δ -methyl group of the L154 side chain buttresses the backbone atoms of H122 (backbone atoms of residues 121–123 shown as dots). (C) Close-up view of NDM-1 shows that the M154 side chain (shown as spheres and sticks) does not exhibit buttressing of H122 backbone atoms (backbone atoms of residues 121–123 shown as dots). (D) Omit map generated by Polder⁶⁷ within PHENIX⁶¹ by omitting NDM-4 residue L154 (side chain shown as sticks) with positive density (green) and negative density (red) drawn at 3.5σ . (E) Omit map generated by Polder⁶⁷ within PHENIX⁶¹ by omitting NDM-12 residue L154 (side chain shown as sticks) with positive density (green) and negative density (red) drawn at 3.5σ .

structure. In contrast, a structural role for the M154L substitution is clear from a close analysis of interactions near the active site. Leu154 more closely buttresses the His122 α -carbon (Figure 6B), as compared to Met154 (Figure 6C), potentially restricting dynamics of the short active-site helical region containing His122 and Asp124 in NDM-4 and NDM-12. We note that only small changes in position or flexibility might be required to achieve the functional differences observed here. For example, changes to hydrophobic residues of carbonic anhydrase that neighbor primary zinc(II) ligands induce only a small difference in the X-ray crystal structure (<1 Å movement of a β -strand) but induce a large (36-fold) change in zinc(II) ion affinity.⁵⁰ In the case of NDM variants, the static structures solved crystallographically indicate no large changes in structure. Comparison of the NDM-1 (4EXY) structure with the NDM-4 and NDM-12 structures shows no significant differences in *B*-factors for residues surrounding the active site, including the 154 and 222 sites or the neighboring β -hairpin

loop, although restraints placed on these positions by the crystal lattice may dampen changes to flexibility in solution. The absence of major structural differences suggest that the observed functional changes in the variants may result from small perturbations to the zinc(II) ligands that impact affinity, conformations accessible to zinc(II) ligands not modeled in their lowest energy state, or changes in the array of dynamic conformations available to primary zinc(II) ligands in each variant. NDM-12 was chosen to investigate the additivity of other substitutions to M154L and because of the proximity of G222D to the active site. Comparison of the NDM-4 and NDM-12 structures suggest that there is no synergistic cooperation of the M154L and G222D sites to alter the structure, although a more extensive analysis of NDM variants will be required to explore interactions of multiple substitutions to structure and function.

In order to more sensitively determine structural differences in solution among the metal ion clusters in NDM variants, we

prepared two alternative metalloforms of each variant, dicobalt(II) and zinc(II)/cobalt(II), the latter of which incorporates cobalt(II) selectively at the metal-2 site coordinated by Cys208, His250, and Asp124. Substitution of diamagnetic zinc(II) with paramagnetic cobalt(II) provides a spectroscopic signal that allows interrogation of changes in the structure induced by each mutation. Previously, the dicobalt(II) and zinc(II)/cobalt(II) metalloforms of NDM-1 have been characterized, and the kinetic parameters (k_{cat} , K_M , k_{cat}/K_M) differ from the dizinc metalloform only by <3-fold, indicating that incorporation of these alternative metals does not greatly perturb the enzyme's function.³¹

UV-vis spectroscopy of dicobalt(II) NDM-1 shows the expected four ligand field bands between 500 and 650 nm and a more intense ligand-to-metal charge transfer band near 320 nm that arises from interaction with the Cys208 thiolate, as reported earlier (Figure S2).³¹ Dicobalt(II) NDM-4 and NDM-12 do now show significant shifts in the position of these absorption bands, although the ligand-field intensities of the two variants are somewhat obscured by a 20% increase in S-to-Co charge-transfer (CT) intensity. The similarity of the optical spectra suggest there are no large scale changes in coordination number or geometry among the dicobalt(II) NDM variants, consistent with the crystal structures described above.

To probe structural differences in finer detail, the dicobalt(II) metalloforms of the three NDM variants were examined by ¹H NMR spectroscopy. The spectrum of dicobalt(II) NDM-1 shows a number of hyperfine shifted resonances, as previously reported (bottom spectrum in Figure 7).³¹ Resonances at 79,




Figure 7. 300 MHz ¹H NMR spectra of dicobalt(II) NDM variants. Spectra are shown for NDM-1, NDM-4 (M154L), and NDM-12 (M154L, G222D). Labels above the NDM-1 spectrum reflect the origin of the signal: metal-1 (1) or metal-2 ligands (2) and metal-2 secondary interactions (2').

72, and 64 ppm correspond to solvent-exchangeable protons of the three His ligands that make up the metal-1 binding site (His120, His122, His189), while resonances at 165, 107, and 48 ppm correspond to Cys208, His250, and Asp124 (metal-2 site ligands). As we showed previously, using heterodimetallic forms of NDM-1, a cobalt(II) in the metal-2 site gives rise to a number of additional resonances from +40 to -65 ppm, arising from second sphere interactions with the penta-coordinate metal-2 site cobalt(II) ion.³¹ The spectrum of dicobalt(II) NDM-1 is strikingly different from that of the dicobalt(II) variants of NDM-4 and NDM-12, though the variant spectra are nearly identical to each other (Figure 7). The spectra show some perturbation of the metal-1 site ligands, with one His proton shifting downfield from 64 ppm, and a significant loss in intensity from the His proton at 79 ppm, which may indicate greater conformational flexibility at the metal-1 site of NDM-4 and -12.

Meanwhile, perturbation of the metal-2 site is more readily apparent. For example, the α -CH₂ protons of Asp124 appear as a magnetically equivalent geminal pair (to similar Co-O-C-H dihedral angles), leading a peak of two-proton intensity at 48 ppm. Both variants show a similar resonance at 48 ppm, at half the intensity seen for dicobalt(II) NDM-1, along with a resonance at 56 ppm of roughly equal intensity. We suggest this may indicate that the carboxylate ligand has rotated some in the variants, leading to inequivalent dihedral angles and chemical shifts. Similarly, the resonances near 160 and 165 ppm for dicobalt(II) NDM-1 suggest a nearly symmetric disposition of the cysteine protons about the Co-S-C plane, and this symmetry is clearly lost in NDM-4 and -12, with the appearance of a new resonance near 200 ppm that lacks an obvious germinal partner. The most likely candidate appears to be a broad line that appears in the region where the metal-1 site His ligands are observed (Figure 7). Such a shift, changing the β -CH₂ proton chemical shift difference from ~5 in NDM-1 to ~120 in NDM-4 and NDM-12, would in turn require a relatively large change in dihedral angle,⁵¹ consistent with the increased CT intensity noted above. The spectra for NDM-4 and -12 also show a significant reduction in the number of secondary contacts at the metal-2 site, on the basis of the observation of fewer resonances below 40 ppm. To verify that most of these changes, as indicated in Figure 7, are localized to the metal-2 site, we generated the zinc(II)/cobalt(II) form of each NDM variant (zinc(II) in the metal-1 site, and cobalt(II) in the metal-2 site). The ¹H NMR spectra of the zinc(II)/cobalt(II) NDM variants (Figure S3) were of insufficient signal-to-noise to reliably identify both Cys proton resonances for NDM-4 and -12, but they support the conclusion above that the mutations in NDM-4 and -12 more clearly affect the metal-2 site.

Finally, CW EPR was used to probe the metal ions directly (Figure 8). Standard perpendicular mode ($B_1 \perp B_0$) spectra




Figure 8. EPR spectra of dicobalt(II) metalloforms of NDM variants. (A) Perpendicular and (B) parallel CW-EPR spectra of dicobalt(II) NDM-1, NDM-4 (M154L), and NDM-12 (M154L, G222D), as labeled, all at 1 mM. The sharp spikes at 1600 G are due to minor contamination by iron in NDM-1, -4, and -12 samples (0.05, 0.1, and 0.1 equiv, respectively).

(Figure 8A) show commonly broad signals from the high-spin cobalt(II) ions. They show only a small difference between the three variants at very low field (~800 G); this small feature has been shown to be diagnostic for a spin-coupled dicobalt(II) system.⁵² The signal appears largest for NDM-1, while being difficult to identify for the other two. This perturbation is reflected in the parallel EPR spectra (Figure 8B), which show a reduction in intensity for the corresponding negative feature at

~800 G. The (negative) intensity of this signal has been correlated to the coupling strength between the cobalt(II) ions in other MBLs,⁵³ and the data in Figure 8 suggest that the mutations in NDM-4 and -12 serve to further decouple the two metal ions.

In conclusion, M154L, the most common point mutation found among clinical variants of NDM, confers enhanced cell viability to ampicillin-treated cultures under conditions where zinc(II) is scarce. The additional mutation in NDM-12 (G222D) can augment this effect in some cases, possibly by a separate additive mechanism. The mutations of NDM-4 and NDM-12 progressively confer additional thermostability at high zinc(II) concentrations and enhanced Zn²⁺ affinity. The selectivity of increased MIC values of these variants for the penam ampicillin is mirrored in kinetic assays using purified enzymes and indicates that improvements in catalysis, rather than increases in overall global stability, are the major factors driving cell survival. Crystal structures of NDM-4 and -12 illustrate the proximity of the mutated sites to the dizinc cluster responsible for catalyzing hydrolysis of β -lactam substrates, and bioinorganic spectroscopy of dicobalt(II) and zinc(II)/cobalt(II) metalloforms reveals how the mutations, predominantly the widespread M154L variation, perturb the structure of the catalytic metal cluster. Taken together, these studies support the proposal that clinical NDM variants are evolving to overcome zinc(II) scarcity found in common sites of infection. Zinc(II) scarcity serves as a selective pressure which may also help explain the success of some nonselective metal chelators to counter NDM-1 activity in animal infection models.^{54,55}

METHODS

Cloning, Expression, and Purification of NDM Variants for Kinetic Characterization. Recombinant, soluble Δ 35 NDM-1 was expressed and purified using a codon-optimized expression plasmid described previously, pET27b-Strep-NDM1, with minor modifications to the protocol.^{35,43} The N-terminal truncation removes a sequence that promotes lipidation⁵⁶ thus allowing expression of a soluble enzyme. Briefly, cultures of *E. coli* BL21(DE3) (pET27b-Strep-NDM1) were grown with shaking at 25 °C in LB growth medium supplemented with 50 μ M ZnSO₄ until reaching mid log phase. Production of NDM-1 was induced upon addition of isopropyl β -D-1-thiogalactopyranoside (0.5 mM) and continued overnight. Cells were pelleted by centrifugation at 2831g for 30 min; the supernatant was discarded, and the pellets were resuspended in NaH₂PO₄ buffer (50 mM) with NaCl (300 mM) at pH 8 for subsequent lysis by sonication. After pelleting and discarding the cell debris, soluble proteins were chromatographed using Qiagen Strep-Tactin Superflow Plus affinity medium using the manufacturer's protocol and desthiobiotin for elution (as described previously).^{35,43} The resulting recombinant soluble NDM-1 protein was dialyzed against two changes of 4 L of storage buffer (50 mM Tris, 150 mM NaCl, pH 7.5). For the kinetic studies reported here, the Strep-affinity tag at the N-terminus of the Δ 35 NDM-1 construct was not removed because k_{cat} and K_M values determined for ampicillin and meropenam (described below) averaged within 0.3-fold of those determined after removal of the Strep tag.³⁵ The NDM-4 (M154L) and NDM-12 (M154L, G222D) variants were prepared in the same way, except that the expression plasmids encoding these proteins were first constructed through QuikChange-PCR mutagenesis using the primers described in Table S7. Before expression, the sequences of the gene inserts

in the expression plasmids encoding each variant (pET27b-Strep-NDM4, pET27b-Strep-NDM12) were verified by sequencing to contain only the intended mutations. The purified recombinant NDM-1, NDM-4, and NDM-12 proteins were each judged to be homogeneous by Coomassie-stained SDS-PAGE analysis (not shown). Concentrations were determined by either Bradford assay (BioRad) or a calculated extinction coefficient for the tagged variants ($\epsilon_{280} = 34\,850\text{ M}^{-1}\text{cm}^{-1}$). The molar zinc(II) content of each was determined using 4-(2-pyridylazo)resorcinol (PAR) in denaturing buffer as described previously,³⁵ with "as purified" NDM-1, NDM-4, and NDM-12 containing 1.5 ± 0.2 , 1.3 ± 0.1 , and 1.2 ± 0.2 mol equiv of zinc(II), respectively. Typical yields for each were ≥ 20 mg protein/1 L culture medium.

Steady-State Kinetic Assays of NDM Variants. Steady-state kinetic parameters (k_{cat} , K_M , k_{cat}/K_M) were determined for NDM-1, NDM-4, and NDM-12 with ampicillin and meropenem (both purchased from Sigma-Aldrich Inc. (St. Louis, MO)) and chromacef (a generous gift from Larry Sutton (Benedictine College, Atchison, KS)) at pH 7.0, in Hepes buffer (50 mM), supplemented by ZnSO₄ (10 μ M for all substrates and also 1 nM for ampicillin), using disposable polystyrene cuvettes (10 mm path length, Thermo Fisher Scientific Inc. (Fair Lawn, NJ)) and a Cary 50 Bio-UV-visible spectrophotometer by following the method described previously.³⁵

To determine the zinc(II) dependence of activity, we followed a previously published procedure, with minor adjustments as noted below.³⁵ Briefly, initial rates were determined for hydrolysis of chromacef (10 μ M, monitored at 442 nm⁴⁴), cephalothin (300 μ M, monitored at 255 nm⁵⁷), ampicillin (1 mM), or meropenem (300 μ M) by each purified NDM variant (40 nM) in the presence of varying ZnSO₄ concentrations (0.1 nM to 100 μ M). When possible, saturating amounts of substrate were used, but lower concentrations were used when the intrinsic absorbance of the substrate was too high. To visualize zinc(II) dependence, observed rates are plotted relative to the maximum observed rate for each variant at any zinc(II) concentration tested.

Cloning of *bla*_{NDM} Variants for Cell Viability Assays.

The *bla*_{NDM-1} gene was cloned from *K. pneumoniae* 246-61A, a clinical isolate from New Delhi, in 2007.⁵⁸ The upstream primer was designed to include the native promoter and lipidation signal (lipobox), as well as to retain the initial 35 residues that are omitted from constructs used to produce soluble protein for kinetic characterization (above). Both forward and reverse oligomers included a *Bam*H1 restriction site for cloning. The PCR product was first cloned into the PCR XL-TOPO vector (Invitrogen, Carlsbad, CA). After verification by sequencing, the XL-TOPO clone was digested with *Bam*H1 and the NDM-1 sequence was inserted into *Bam*H1 digested pHSG-298 vector (Takara, Dalian, China).

On the basis of the NDM-1/pHSG298 construct, sequences encoding NDM-4 and NDM-12 were generated by Celtek Biosciences (Franklin, TN) and cloned into the pBluescript II SK(+) vector. The sequence was designed with flanking *Xba*I and *Bam*H1 restriction sites in order to clone the sequence into the pHSG298 vector in the same orientation as NDM-1/pHSG298. Following restriction digest of each NDM/pBluescript SK(+) construct and pHSG298 with *Xba*I and *Bam*H1, the sequences encoding NDM-4 and NDM-12 were ligated into the pHSG298 vector. *E. coli* DH10B were transformed

with the resulting vector, and the inserted sequences were verified by DNA sequencing.

The QuikChange XL site-directed mutagenesis kit (Agilent, Santa Clara, CA) was used to generate all the remaining variants at the codon encoding M154 in the NDM-1/pHSG298 construct, following the manufacturer's protocol. For PCR mutagenesis, four degenerate complementary primer sets and ten specific complementary primer sets were used to generate the remaining 18 amino acid variants (Thermo Fisher Scientific, Hampton, NH) (Table S8). The resulting plasmids were used to transform *E. coli* DH10B, and the inset sequences were verified by DNA sequencing.

Minimum Inhibitory Concentration Measurements.

MIC measurements were performed in triplicate using the Mueller-Hinton agar dilution method according to the Clinical Laboratory and Standards Institute (CLSI) protocol.⁵⁹ We performed all cell viability assays in *E. coli* DH10B, in order to provide a uniform genetic background in which to evaluate the impact of single amino acid changes. Briefly, bacterial cultures containing *bla*_{NDM} variants cloned into a uniform vector were grown overnight at 37 °C in Mueller-Hinton (M-H) broth. The cultures were diluted, and a Steers replicator was used to deliver 10 μ L of a diluted overnight culture containing approximately 10⁴ CFU. MICs were determined for the following: imipenem, meropenem (Fresenius Kabi); cefepime (WG Critical Care); ampicillin, cephalothin, ceftazidime, and cefotaxime (Sigma-Aldrich). MICs were also determined (as above) with the addition of 50 μ M EDTA (United States Biochemical Corp.) to the Mueller-Hinton agar in order to limit zinc(II) availability.

Immunoblotting. Immunoblotting was used to evaluate the expression levels of NDM-1 and variants. Five milliliter cultures of *E. coli* DH10B cells containing pHSG-298 phagemids harboring the various *bla*_{NDM} variants in Mueller-Hinton (MH) broth containing 50 μ g/mL kanamycin were grown at 37 °C to an optical density at 600 nm (OD₆₀₀) of 0.8. Fifty microliter aliquots of whole cells from these cultures were pelleted and frozen overnight. Pellets were resuspended in 20 μ L of loading dye, separated by SDS-PAGE, and transferred to a polyvinylidene difluoride membrane (Novex, Life Technologies, Carlsbad, CA) by electroblotting. After blocking for 1 h with 5% nonfat dry milk, *bla*_{NDM} presence on the blot was detected by incubation in 5% nonfat dry milk with anti-NDM-1 polyclonal antibody mouse serum (1/200 dilution) and 1/10 000 dilution of mouse anti-DnaK monoclonal Ab (Enzo Life Sciences) overnight at 4 °C. The membrane was washed four times, 15 min each, in Tris-buffered saline (pH 7.4) containing 0.1% Tween-20 and subsequently incubated in 5% nonfat dry milk with 1/10 000 dilution of HRP-goat antimouse Ab conjugate (Santa Cruz Biotechnology). After four additional washes, the membrane was processed for exposure using the ECL kit (GE Healthcare) and FOTO/AnalystVR FX (Fotodyne).

PAR Competition Assay. Using an established assay,⁴⁸ we determined the K_d values for the Zn2 site (the labile zinc ion in NDM-1³⁵) for each of the soluble Δ 35 NDM variants. Briefly, the colorimetric chelator 4-(2-pyridylazo)resorcinol (PAR, 10 μ M, Sigma-Aldrich) is incubated with ZnSO₄ (4 μ M, diluted from a 0.1 M ZnSO₄ standard solution, Sigma-Aldrich) in HEPES Buffer (50 mM) at pH 7.4 and then titrated with the "as purified" NDM-1, NDM-4, and NDM-12 (0–40 μ M). At each condition, concentrations of the ZnH_x(PAR)₂ complex and total protein were calculated from absorbance values at 492

and 280 nm, respectively, and K_d values were derived from fits as described elsewhere.⁴⁸

Cloning, Expression, and Purification of NDM Variants for DSF and Crystallography. The NDM-1 coding sequence used for expressing Δ 35 NDM-1 was cloned into a pET-24a vector to produce plasmid encoding residues 42–270 with a stop codon inserted immediately after the codon for residue 270 to express a tagless soluble Δ 42 NDM-1 construct that better promotes crystallization. NDM-4 and NDM-12 variants were produced by site directed mutagenesis using the pET24a-NDM-1 construct as a template. NDM variants for DSF and crystallography were expressed in BL21(DE3) *E. coli* cells grown in Terrific broth. Cells were harvested and resuspended in 25 mM HEPES, pH 7.5, 150 mM NaCl, 1 mg/mL lysozyme (Sigma), 20 μ g/mL DNaseI (MP Biomedicals), and 100 μ g/mL 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (Gold Biotechnology). Cells were immediately frozen in liquid nitrogen and thawed at 4 °C with rotation the night before purification. Cell lysate was clarified by centrifugation at 17 000g for 45 min, followed by filtration of the supernatant through a 0.45 μ M filter (Fisher). Lysate was dialyzed against 20 mM HEPES, pH 7.6, 100 μ M ZnCl₂. Dialyzed lysate was loaded onto a HiPrep Q FF 16/10 sepharose column (GE Healthcare), and NDM-1, NDM-4, or NDM-12 was eluted using a linear gradient of dialysis buffer and increasing percentage of 20 mM HEPES, pH 7.6, 500 mM NaCl, 100 μ M ZnCl₂. Protein eluted from the anion exchange column was concentrated using 5 kDa MWCO centrifugal concentrators prior to loading onto a HiLoad 16/600 superdex 75 (S75) size exclusion column (GE Healthcare) equilibrated with 20 mM HEPES, pH 7.6. S75 elution fractions containing NDM-1, NDM-4, or NDM-12 were concentrated and purified by an additional round of size exclusion chromatography using identical parameters. Final S75 elution fractions were concentrated using 5 kDa MWCO centrifugal concentrators prior to use for DSF or crystallization trials.

DSF Studies. Aliquots of 50 μ M NDM-1, NDM-4, and NDM-12 were treated with EDTA to remove zinc, followed by extensive dialysis against 20 mM HEPES, pH 7.5, 150 mM NaCl. Briefly, NDM-1, NDM-4, and NDM-12 samples were dialyzed twice against 2 mM EDTA, 20 mM HEPES, pH 7.5, 150 mM NaCl, followed by three separate dialysis steps against 20 mM HEPES, pH 7.5, 150 mM NaCl, 0.5 mM TCEP, and a small scoop of Chelex resin. Buffers were exchanged with approximately 12 h intervals. Zinc-depleted NDM-1, NDM-4, and NDM-12 samples were then diluted to a final concentration of 5 μ M into 20 mM HEPES, pH 7.5, 150 mM NaCl, 5 \times SYPRO Orange (Pierce Thermo Inc.), and ZnCl₂ at a range of zinc concentrations from 0.25 to 50 μ M. Protein samples were dispensed into a 96-well Frame Star PCR plate sealed with a clear thermal-seal film to prevent evaporation. DSF data was collected on a CFX96 RT-PCR (Bio-Rad) via the preset "HEX" channel for fluorescence excitation and emission. Temperature was increased in 0.5 °C increments with a five second equilibration at each step. Fluorescence intensity data was fit to Boltzmann Sigmoidal curve using Prism (GraphPad, Inc.) to determine the melting temperature (T_m) of all proteins. T_m values across the range of zinc concentrations were fit to sigmoidal curves using Prism.

X-ray Crystallography. Crystallization screening for NDM-4 and NDM-12 was carried out by preparing 96-well sitting drop vapor diffusion screens using a Phoenix crystallization robot (Art Robbins Instruments). The 800 nL

sitting drops consisted of a 1:1 ratio of 1.6 mM protein and crystallization condition. Initial screening was carried out using the sparse matrix crystallization screens MCSG 1-4 (Microlytic). Optimization of initial NDM-4 hits produced diffraction quality crystals in 0.1 M bis-Tris, pH 6.5, and 20% (w/v) polyethylene glycol monomethyl ether 550. Optimization of NDM-12 hits yielded diffraction quality crystals in 0.2 M ammonium iodide and 20% (w/v) polyethylene glycol. Crystals were harvested using 50 μm MicroLoops (MiTeGen) and were cryoprotected by transfer through LV CryoOil (MiTeGen) and frozen in liquid nitrogen. Single crystal X-ray diffraction data were collected at 1.0000 Å on beamline 4.2.2 at the Advanced Light Source (ALS), Lawrence Berkeley National Laboratory.

Phases for NDM-4 were calculated by molecular replacement using the PHASER⁶⁰ component of PHENIX⁶¹ with the zinc-bound structure of NDM-4 (accession code 4TYF). The molecular replacement solution for the NDM-4 data set resulted in a TFZ-score of 33.6 and a log likelihood gain of 17 847. Phases for NDM-12 were calculated by molecular replacement using PHASER within PHENIX using the final, refined structure of NDM-4 (chain A) reported in this manuscript. The molecular replacement solution for the NDM-12 data set resulted in a TFZ-score of 29.1 and a log likelihood gain of 7016. Each molecular replacement solution was subjected to iterative rounds of model building in Coot⁶² and refinement in PHENIX using individual anisotropic *B*-factors and TLS refinement⁶³ for all protein atoms and individual isotropic *B*-factors for the solvent. All molecular structure factors have been deposited in the PDB (NDM-4 accession code 5WIG; NDM-12 accession code 5WIH). Stereochemical and geometric quality analyses of the NDM-4 and NDM-12 structures were performed with MolProbity version 4.3.1.⁶⁴ The final NDM-4 structure, in space group *P12₁1*, contains two chains per asymmetric unit that superimpose with 0.116 Å RMSD. Each NDM-4 chain superimposes onto the previously reported zinc-bound structure of NDM-4 (accession code 4TYF) with 0.16 and 0.19 Å RMSD. Both chains within the NDM-4 asymmetric unit feature two bound zinc ions and resolved electron density for all amino residues present in the crystallized construct (residues 42–270), including the beta-hairpin above the active site. Bound waters (608) were resolved bound to either or both chains within the NDM-4 asymmetric unit, while no electron density was observed for additional buffer components.

The final NDM-12 structure, also solved in space group *P12₁1*, contains a single protein chain per asymmetric unit. The chain features two bound zinc ions and resolved electron density for all amino residues present in the crystallized construct (residues 42–270), including the beta-hairpin above the active site. Bound waters (233) were resolved within the electron density of the NDM-12 asymmetric unit, while no electron density was observed for additional buffer components.

Preparation of Dicobalt(II) and Zinc(II)/Cobalt(II) Metalloforms of NDM Variants. The dicobalt(II) metalloforms of purified, tagless, $\Delta 28$ -NDM-1, -4, and -12 were prepared through a process of chelation, denaturation, refolding, and addition of cobalt(II) ions. Each purified protein was placed within a 10 kDa molecular weight cutoff membrane dialysis bag and allowed to equilibrate against 1 L of dialysis buffer (unless otherwise noted) for 8 h at 4 °C before changing to the subsequent dialysis buffer to include a series of 11 dialysis steps: four changes of Buffer A (50 mM HEPES, 150

mM NaCl at pH 6.8) with EDTA (2 mM); urea (6 M, 0.5 L); six changes of Buffer A. The resulting apo-enzymes for each NDM variant were quantified with UV–vis ($\epsilon_{280} = 27\,960\ \text{M}^{-1}\text{cm}^{-1}$) and concentrated to 1 mM. The dicobalt(II) metalloforms of each NDM variant were then prepared by addition of 2 mol equiv of CoCl_2 (Strem Chemicals Inc., #27-0405), which in each case resulted in a color change of the solution from colorless to pink.

Zinc(II)/cobalt(II) metalloforms of each NDM variant were prepared as described previously for NDM-1 to generate metalloforms that predominantly place zinc(II) in the metal-1 site (coordinated by three His residues) and cobalt(II) in the metal-2 site (coordinated by Cys, His, and Asp residues).³¹

UV–Vis Spectroscopy. Apo-NDM-1, -4, and -12 were diluted to 300 μM in Buffer A. Two molar equivalents of CoCl_2 , from a 50 mM stock solution, were added to each protein on ice. Each sample was added to a 500 μL quartz cuvette, and UV–vis spectra were collected with a PerkinElmer Lambda 750 UV/vis/IR spectrometer measuring absorbance from 300 to 700 nm at room temperature. A blank spectrum of Buffer A was used to generate difference spectra. All data was normalized at 700 nm.

¹H NMR Spectroscopy. NMR samples were buffered with HEPES (50 mM), NaCl (150 mM) at pH 6.8, with 10% D_2O (v/v). Each sample (300 μL) was added to a D_2O matched Shigemi Advanced NMR microtube with a 5 mm outer diameter. Spectra were collected at 292 K on a Bruker ASX300 (BBI probe) ¹H NMR operated at a frequency of 300.16 MHz. Spectra were collected using a frequency-switching method, applying a long, low power (270 ms) pulse centered at the water frequency, followed by a high power 3 μs pulse centered at 90 ppm.⁶⁵ This method allows for suppression of the water signal with enhancement of severely hyperfine-shifted resonances. Spectra consisted of 30 000 transients of 16 k data points over a 333 ppm spectral window ($t_{\text{aq}} \approx 51$ ms); signal averaging took approximately 3 h per spectrum.

EPR Spectroscopy. EPR samples containing NDM-1, -4, and -12 included approximately 10% (v/v) glycerol as glassing agent. Samples were loaded into EPR tubes, degassed by repeated evacuation/purgation with N_2 prior to data collection. Spectra were collected on a Bruker EMX EPR spectrometer, equipped with an ER4116-DM dual mode resonator (9.37 GHz, parallel; 9.62 GHz perpendicular). The data in EPR figures were scaled so that the *X*-axes matched (perpendicular mode field values were scaled by 9.37/9.62). Temperature control was accomplished using an Oxford ESR900 cryostat and temperature controller (4.5 K). Other spectral conditions included: microwave power = 0.2 mW; field modulation = 10 G (100 kHz); receiver gain = 10^4 ; time constant/conversion time = 41 ms.

■ ASSOCIATED CONTENT

📄 Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsinfecdis.7b00128.

Structures of β -lactams used, MIC determinations, UV–vis and ¹H NMR spectra of NDM metalloforms, and primers used for mutagenesis (PDF)

Accession Codes

Coordinates and structure factors for NDM-4 and NDM-12 have been deposited in the Protein Data Bank with accession codes SWIG and SWIH, respectively.

AUTHOR INFORMATION

Corresponding Authors

*E-mail: walt.fast@austin.utexas.edu (W.F.).

*E-mail: Robert.Bonomo@va.gov (R.A.B.).

*E-mail: crowdemw@miamioh.edu (M.W.C.).

*E-mail: pagerc@miamioh.edu (R.C.P.).

*E-mail: dtierney@miamioh.edu (D.L.T.).

ORCID

Richard C. Page: [0000-0002-3006-3171](https://orcid.org/0000-0002-3006-3171)

Michael W. Crowder: [0000-0002-3138-0283](https://orcid.org/0000-0002-3138-0283)

Robert A. Bonomo: [0000-0002-3299-894X](https://orcid.org/0000-0002-3299-894X)

Walter Fast: [0000-0001-7567-2213](https://orcid.org/0000-0001-7567-2213)

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported in part by the National Institutes of Health, National Institute of General Medical Sciences, and National Institute of Allergy and Infectious Disease under award numbers GM111926, R01AI100560 (to R.A.B.), R01AI063517 (to R.A.B.), and R01AI072219 (to R.A.B.), by the National Science Foundation (CHE-1509285 to M.W.C. and D.L.T.), by the Robert A. Welch Foundation (F-1572 to W.F.), and by Miami University through the Robert H. and Nancy J. Blayney Professorship (to R.C.P.). This study was also supported in part by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, Award Number 1I01BX001974 (to R.A.B.) from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development and the Geriatric Research Education and Clinical Center VISN 10 (to R.A.B.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Veterans Affairs. The Advanced Light Source is supported by the US Department of Energy under contract number DE-AC03-76SF00098 at Lawrence Berkeley National Laboratory. R.A.B. and C.R.B. thank Dr. Brad Spellberg (Professor, USC) for the gift of anti-NDM-1 polyclonal antibody mouse serum.

REFERENCES

- (1) Yong, D., Toleman, M. A., Giske, C. G., Cho, H. S., Sundman, K., Lee, K., and Walsh, T. R. (2009) Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in *Klebsiella pneumoniae* sequence type 14 from India. *Antimicrob. Agents Chemother.* 53 (12), 5046–54.
- (2) Kaase, M., Nordmann, P., Wichelhaus, T. A., Gatermann, S. G., Bonnin, R. A., and Poirel, L. (2011) NDM-2 carbapenemase in *Acinetobacter baumannii* from Egypt. *J. Antimicrob. Chemother.* 66 (6), 1260–2.
- (3) Tada, T., Miyoshi-Akiyama, T., Shimada, K., and Kirikae, T. (2014) Biochemical analysis of metallo-beta-lactamase NDM-3 from a multidrug-resistant *Escherichia coli* strain isolated in Japan. *Antimicrob. Agents Chemother.* 58 (6), 3538–40.
- (4) Nordmann, P., Boulanger, A. E., and Poirel, L. (2012) NDM-4 metallo-beta-lactamase with increased carbapenemase activity from *Escherichia coli*. *Antimicrob. Agents Chemother.* 56 (4), 2184–6.

- (5) Hornsey, M., Phee, L., and Wareham, D. W. (2011) A novel variant, NDM-5, of the New Delhi metallo-beta-lactamase in a multidrug-resistant *Escherichia coli* ST648 isolate recovered from a patient in the United Kingdom. *Antimicrob. Agents Chemother.* 55 (12), 5952–4.

- (6) Williamson, D. A., Sidjabat, H. E., Freeman, J. T., Roberts, S. A., Silvey, A., Woodhouse, R., Mowat, E., Dyet, K., Paterson, D. L., Blackmore, T., Burns, A., and Heffernan, H. (2012) Identification and molecular characterisation of New Delhi metallo-beta-lactamase-1 (NDM-1)- and NDM-6-producing Enterobacteriaceae from New Zealand hospitals. *Int. J. Antimicrob. Agents* 39 (6), 529–33.

- (7) Gottig, S., Hamprecht, A. G., Christ, S., Kempf, V. A., and Wichelhaus, T. A. (2013) Detection of NDM-7 in Germany, a new variant of the New Delhi metallo-beta-lactamase with increased carbapenemase activity. *J. Antimicrob. Chemother.* 68 (8), 1737–40.

- (8) Tada, T., Miyoshi-Akiyama, T., Dahal, R. K., Sah, M. K., Ohara, H., Kirikae, T., and Pokhrel, B. M. (2013) NDM-8 metallo-beta-lactamase in a multidrug-resistant *Escherichia coli* strain isolated in Nepal. *Antimicrob. Agents Chemother.* 57 (5), 2394–6.

- (9) Wang, X., Li, H., Zhao, C., Chen, H., Liu, J., Wang, Z., Wang, Q., Zhang, Y., He, W., Zhang, F., and Wang, H. (2014) Novel NDM-9 metallo-beta-lactamase identified from a ST107 *Klebsiella pneumoniae* strain isolated in China. *Int. J. Antimicrob. Agents* 44 (1), 90–1.

- (10) Khajuria, A., Praharaj, A. K., Kumar, M., and Grover, N. (2016) Presence of a novel variant NDM-10, of the New Delhi metallo-beta-lactamase in a *Klebsiella pneumoniae* isolate. *Indian J. Med. Microbiol.* 34 (1), 121–3.

- (11) Tada, T., Shrestha, B., Miyoshi-Akiyama, T., Shimada, K., Ohara, H., Kirikae, T., and Pokhrel, B. M. (2014) NDM-12, a novel New Delhi metallo-beta-lactamase variant from a carbapenem-resistant *Escherichia coli* clinical isolate in Nepal. *Antimicrob. Agents Chemother.* 58 (10), 6302–5.

- (12) Shrestha, B., Tada, T., Miyoshi-Akiyama, T., Shimada, K., Ohara, H., Kirikae, T., and Pokhrel, B. M. (2015) Identification of a novel NDM variant, NDM-13, from a multidrug-resistant *Escherichia coli* clinical isolate in Nepal. *Antimicrob. Agents Chemother.* 59 (9), 5847–50.

- (13) Zou, D., Huang, Y., Zhao, X., Liu, W., Dong, D., Li, H., Wang, X., Huang, S., Wei, X., Yan, X., Yang, Z., Tong, Y., Huang, L., and Yuan, J. (2015) A novel New Delhi metallo-beta-lactamase variant, NDM-14, isolated in a Chinese Hospital possesses increased enzymatic activity against carbapenems. *Antimicrob. Agents Chemother.* 59 (4), 2450–3.

- (14) Kazmierczak, K. M., Rabine, S., Hackel, M., McLaughlin, R. E., Biedenbach, D. J., Bouchillon, S. K., Sahm, D. F., and Bradford, P. A. (2016) Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-beta-Lactamase-Producing Enterobacteriaceae and *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* 60 (2), 1067–78.

- (15) Liu, Z., Wang, Y., Walsh, T. R., Liu, D., Shen, Z., Zhang, R., Yin, W., Yao, H., Li, J., and Shen, J. (2017) Plasmid-Mediated Novel blaNDM-17 Gene Encoding a Carbapenemase with Enhanced Activity in a Sequence Type 48 *Escherichia coli* Strain. *Antimicrob. Agents Chemother.* 61 (5), e02233-16.

- (16) Rahman, M., Prasad, K. N., Pathak, A., Singh, A., Mukherjee, C., Ahmad, S., and Zorn, B. G. (2015) Prevalence and molecular characterisation of NDM-4, NDM-5, NDM-7, NDM-8 and a novel variant of the New Delhi Metallo-beta-lactamase NDM-11 in Enterobacteriaceae from South India, in *GenBank*, KP265939.1.

- (17) Basu, S., and Mitra, S. (2015) A new metallo-beta-lactamase NDM-15 in an *Escherichia coli* isolated from the blood of a septicemic neonate in West Bengal, India, in *GenBank*, KP735848.1.

- (18) Mojica, M. F., Bonomo, R. A., and Fast, W. (2016) B1-Metallo-beta-Lactamases: Where Do We Stand? *Curr. Drug Targets* 17 (9), 1029–1050.

- (19) Lange, F., Pfennigwerth, N., Schauer, J., and Gatermann, S. G. (2017) Novel NDM variant found in *Escherichia coli*, in *GenBank*, KY503030.1.

- (20) Bush, K., and Fisher, J. F. (2011) Epidemiological expansion, structural studies, and clinical challenges of new beta-lactamases from gram-negative bacteria. *Annu. Rev. Microbiol.* 65, 455–78.
- (21) Patel, M. P., Hu, L., Stojanoski, V., Sankaran, B., Prasad, B. V. V., and Palzkill, T. (2017) The Drug-Resistant Variant P167S Expands the Substrate Profile of CTX-M beta-Lactamases for Oxymino-Cephalosporin Antibiotics by Enlarging the Active Site upon Acylation. *Biochemistry* 56 (27), 3443–3453.
- (22) Makena, A., Brem, J., Pfeffer, I., Geffen, R. E., Wilkins, S. E., Tarhonskaya, H., Flashman, E., Phee, L. M., Wareham, D. W., and Schofield, C. J. (2015) Biochemical characterization of New Delhi metallo-beta-lactamase variants reveals differences in protein stability. *J. Antimicrob. Chemother.* 70 (2), 463–9.
- (23) Palmer, L. D., and Skaar, E. P. (2016) Transition Metals and Virulence in Bacteria. *Annu. Rev. Genet.* 50, 67–91.
- (24) Chipperfield, J. R., and Ratledge, C. (2000) Salicylic acid is not a bacterial siderophore: a theoretical study. *BioMetals* 13 (2), 165–8.
- (25) Sandy, M., and Butler, A. (2009) Microbial iron acquisition: marine and terrestrial siderophores. *Chem. Rev.* 109 (10), 4580–95.
- (26) Hood, M. I., and Skaar, E. P. (2012) Nutritional immunity: transition metals at the pathogen-host interface. *Nat. Rev. Microbiol.* 10 (8), 525–37.
- (27) Outten, C. E., and O'Halloran, T. V. (2001) Femtomolar sensitivity of metalloregulatory proteins controlling zinc homeostasis. *Science* 292 (5526), 2488–92.
- (28) Hensley, M. P., Tierney, D. L., and Crowder, M. W. (2011) Zn(II) binding to *Escherichia coli* 70S ribosomes. *Biochemistry* 50 (46), 9937–9.
- (29) Johnstone, T. C., and Nolan, E. M. (2015) Beyond iron: non-classical biological functions of bacterial siderophores. *Dalton Trans* 44 (14), 6320–39.
- (30) Zhang, H., and Hao, Q. (2011) Crystal structure of NDM-1 reveals a common beta-lactam hydrolysis mechanism. *FASEB J.* 25 (8), 2574–82.
- (31) Yang, H., Aitha, M., Marts, A. R., Hetrick, A., Bennett, B., Crowder, M. W., and Tierney, D. L. (2014) Spectroscopic and mechanistic studies of heterodimetallic forms of metallo-beta-lactamase NDM-1. *J. Am. Chem. Soc.* 136 (20), 7273–85.
- (32) Schilling, O., Wenzel, N., Naylor, M., Vogel, A., Crowder, M., Makaroff, C., and Meyer-Klaucke, W. (2003) Flexible metal binding of the metallo-beta-lactamase domain: glyoxalase II incorporates iron, manganese, and zinc in vivo. *Biochemistry* 42 (40), 11777–86.
- (33) Hu, Z., Gunasekera, T. S., Spadafora, L., Bennett, B., and Crowder, M. W. (2008) Metal content of metallo-beta-lactamase L1 is determined by the bioavailability of metal ions. *Biochemistry* 47 (30), 7947–53.
- (34) Cahill, S. T., Tarhonskaya, H., Rydzik, A. M., Flashman, E., McDonough, M. A., Schofield, C. J., and Brem, J. (2016) Use of ferrous iron by metallo-beta-lactamases. *J. Inorg. Biochem.* 163, 185–193.
- (35) Thomas, P. W., Zheng, M., Wu, S., Guo, H., Liu, D., Xu, D., and Fast, W. (2011) Characterization of purified New Delhi metallo-beta-lactamase-1. *Biochemistry* 50 (46), 10102–13.
- (36) Jayaram, L., Chunilal, S., Pickering, S., Ruffin, R. E., and Zalewski, P. D. (2011) Sputum zinc concentration and clinical outcome in older asthmatics. *Respirology* 16 (3), 459–66.
- (37) Bouatra, S., Aziat, F., Mandal, R., Guo, A. C., Wilson, M. R., Knox, C., Bjorn Dahl, T. C., Krishnamurthy, R., Saleem, F., Liu, P., Dame, Z. T., Poelzer, J., Huynh, J., Yallou, F. S., Psychogios, N., Dong, E., Bogumil, R., Roehring, C., and Wishart, D. S. (2013) The human urine metabolome. *PLoS One* 8 (9), e73076.
- (38) Gray, R. D., Duncan, A., Noble, D., Imrie, M., O'Reilly, D. S., Innes, J. A., Porteous, D. J., Greening, A. P., and Boyd, A. C. (2010) Sputum trace metals are biomarkers of inflammatory and suppurative lung disease. *Chest* 137 (3), 635–41.
- (39) Smith, D. J., Anderson, G. J., Bell, S. C., and Reid, D. W. (2014) Elevated metal concentrations in the CF airway correlate with cellular injury and disease severity. *J. Cystic Fibrosis* 13 (3), 289–95.
- (40) Gonzalez, J. M., Meini, M. R., Tomatis, P. E., Medrano Martin, F. J., Cricco, J. A., and Vila, A. J. (2012) Metallo-beta-lactamases withstand low Zn(II) conditions by tuning metal-ligand interactions. *Nat. Chem. Biol.* 8 (8), 698–700.
- (41) Gonzalez, L. J., Bahr, G., Nakashige, T. G., Nolan, E. M., Bonomo, R. A., and Vila, A. J. (2016) Membrane anchoring stabilizes and favors secretion of New Delhi metallo-beta-lactamase. *Nat. Chem. Biol.* 12 (7), 516–22.
- (42) Hurst, T. K., Wang, D., Thompson, R. B., and Fierke, C. A. (2010) Carbonic anhydrase II-based metal ion sensing: Advances and new perspectives. *Biochim. Biophys. Acta, Proteins Proteomics* 1804 (2), 393–403.
- (43) Thomas, P. W., Spicer, T., Cammarata, M., Brodbelt, J. S., Hodder, P., and Fast, W. (2013) An altered zinc-binding site confers resistance to a covalent inactivator of New Delhi metallo-beta-lactamase-1 (NDM-1) discovered by high-throughput screening. *Bioorg. Med. Chem.* 21 (11), 3138–46.
- (44) Yu, S., Vosbeek, A., Corbella, K., Severson, J., Schesser, J., and Sutton, L. D. (2012) A chromogenic cephalosporin for beta-lactamase inhibitor screening assays. *Anal. Biochem.* 428 (2), 96–8.
- (45) Yang, H., Young, H., Yu, S., Sutton, L., and Crowder, M. W. (2014) Targeting metallo-carbapenemases via modulation of electronic properties of cephalosporins. *Biochem. J.* 464 (2), 271–9.
- (46) Wommer, S., Rival, S., Heinz, U., Galleni, M., Frere, J. M., Franceschini, N., Amicosante, G., Rasmussen, B., Bauer, R., and Adolph, H. W. (2002) Substrate-activated zinc binding of metallo-beta-lactamases: physiological importance of mononuclear enzymes. *J. Biol. Chem.* 277 (27), 24142–7.
- (47) Llarrull, L. I., Tioni, M. F., and Vila, A. J. (2008) Metal content and localization during turnover in *B. cereus* metallo-beta-lactamase. *J. Am. Chem. Soc.* 130 (47), 15842–51.
- (48) Kocyla, A., Pomorski, A., and Krezel, A. (2015) Molar absorption coefficients and stability constants of metal complexes of 4-(2-pyridylazo)resorcinol (PAR): Revisiting common chelating probe for the study of metalloproteins. *J. Inorg. Biochem.* 152, 82–92.
- (49) Ferguson, J. A., Makena, A., Brem, J., McDonough, M. A., and Schofield, C. J. (2015) Structure of a Metallo-beta-lactamase, in *Protein Data Bank*, 4TYF.
- (50) Cox, J. D., Hunt, J. A., Compher, K. M., Fierke, C. A., and Christianson, D. W. (2000) Structural influence of hydrophobic core residues on metal binding and specificity in carbonic anhydrase II. *Biochemistry* 39 (45), 13687–94.
- (51) Bertini, I., Turano, P., and Vila, A. J. (1993) Nuclear Magnetic Resonance of Paramagnetic Metalloproteins. *Chem. Rev.* 93, 2833–2932.
- (52) Bennett, B. (2010) EPR of Cobalt-Substituted Zinc Enzymes. *Biol. Magn. Reson.* 29, 345–371.
- (53) Tioni, M. F., Llarrull, L. I., Poeylout-Palena, A. A., Marti, M. A., Saggi, M., Periyannan, G. R., Mata, E. G., Bennett, B., Murgida, D. H., and Vila, A. J. (2008) Trapping and characterization of a reaction intermediate in carbapenem hydrolysis by *B. cereus* metallo-beta-lactamase. *J. Am. Chem. Soc.* 130 (47), 15852–63.
- (54) Yoshizumi, A., Ishii, Y., Livermore, D. M., Woodford, N., Kimura, S., Saga, T., Harada, S., Yamaguchi, K., and Tateda, K. (2013) Efficacies of calcium-EDTA in combination with imipenem in a murine model of sepsis caused by *Escherichia coli* with NDM-1 beta-lactamase. *J. Infect. Chemother.* 19 (5), 992–5.
- (55) King, A. M., Reid-Yu, S. A., Wang, W., King, D. T., De Pascale, G., Strynadka, N. C., Walsh, T. R., Coombes, B. K., and Wright, G. D. (2014) Aspergillomarasmine A overcomes metallo-beta-lactamase antibiotic resistance. *Nature* 510 (7506), 503–6.
- (56) King, D., and Strynadka, N. (2011) Crystal structure of New Delhi metallo-beta-lactamase reveals molecular basis for antibiotic resistance. *Protein Sci.* 20 (9), 1484–91.
- (57) Cantu, C., 3rd, and Palzkill, T. (1998) The role of residue 238 of TEM-1 beta-lactamase in the hydrolysis of extended-spectrum antibiotics. *J. Biol. Chem.* 273 (41), 26603–9.
- (58) Castanheira, M., Deshpande, L. M., Mathai, D., Bell, J. M., Jones, R. N., and Mendes, R. E. (2011) Early dissemination of NDM-1- and

OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006–2007. *Antimicrob. Agents Chemother.* 55 (3), 1274–8.

(59) CLSI. (2015) *Performance Standards for Antimicrobial Susceptibility Testing*, 24th Informational Supplement, Clinical and Laboratory Standards Institute, Wayne, PA.

(60) McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software. *J. Appl. Crystallogr.* 40 (Pt 4), 658–674.

(61) Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* 66 (Pt 2), 213–221.

(62) Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* 66 (Pt 4), 486–501.

(63) Painter, J., and Merritt, E. A. (2006) Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* 62 (Pt 4), 439–450.

(64) Chen, V. B., Arendall, W. B., 3rd, Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., and Richardson, D. C. (2010) MolProbity: all-atom structure validation for macromolecular crystallography. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* 66 (Pt 1), 12–21.

(65) Riley, E. A., Petros, A. K., Smith, K. A., Gibney, B. R., and Tierney, D. L. (2006) Frequency-switching inversion-recovery for severely hyperfine-shifted NMR: evidence of asymmetric electron relaxation in high-spin Co(II). *Inorg. Chem.* 45 (25), 10016–8.

(66) King, D. T., Worrall, L. J., Gruninger, R., and Strynadka, N. C. (2012) New Delhi metallo-beta-lactamase: structural insights into beta-lactam recognition and inhibition. *J. Am. Chem. Soc.* 134 (28), 11362–5.

(67) Liebschner, D., Afonine, P. V., Moriarty, N. W., Poon, B. K., Sobolev, O. V., Terwilliger, T. C., and Adams, P. D. (2017) Polder maps: improving OMIT maps by excluding bulk solvent. *Acta Crystallogr. D, Struct. Biol.* 73 (Pt 2), 148–157.